Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease

NCT06006819 is registered in ClinicalTrials.gov with Cheng-Hsin General Hospital as lead sponsor.

NCT NCT06006819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06006819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease
Lead sponsor
Cheng-Hsin General Hospital
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2023
Completion date
December 23, 2025
Enrollment
155 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute heart failure, biomarker, chronic kidney diseases